COMMUNIQUÉS West-GlobeNewswire

-
Assure Holdings Announces Results of Annual General Meeting of Shareholders
30/11/2018 -
Wildflower Posts 9th Consecutive Quarter With Increased Revenue
30/11/2018 -
SELLAS to Present Further Correlative Data from Phase 2b Trial of NeuVax + Herceptin® at the 2018 San Antonio Breast Cancer Symposium
30/11/2018 -
Oncology Venture A/S: Publication of financial report Q3 2018
30/11/2018 -
Cocrystal Pharma Announces Presentation at the RespiDART 2018: Frontiers in Drug Development Against Respiratory Viruses Conference
30/11/2018 -
IntelGenx Engages Focus Communications for Investor Relations Program
30/11/2018 -
Calithera Biosciences to Participate in the 2018 Citi Global Healthcare Conference
30/11/2018 -
Inspire Medical Systems, Inc. Announces Publication of Data From ADHERE Registry
30/11/2018 -
Brain Scientific To Introduce Two FDA Cleared Devices At American Epilepsy Society Annual Meeting
30/11/2018 -
Biohit Oyj’s Financial Reporting and Annual General Meeting in 2019
30/11/2018 -
TG Therapeutics, Inc. Recaps Triple Therapy Data Presentations at the Upcoming 60th American Society of Hematology Annual Meeting and Exposition
30/11/2018 -
Lenzilumab Study Published in ‘blood’, the Official Journal of the American Society of Hematology (ASH), First Edition
30/11/2018 -
Editas Medicine Announces FDA Acceptance of IND Application for EDIT-101
30/11/2018 -
Neos Therapeutics Announces Realignment of Commercial Organization
30/11/2018 -
Emerald Health Therapeutics Reports 3rd Quarter 2018 Financial Results and Provides Corporate Update
30/11/2018 -
Stemline Therapeutics Highlights Four ELZONRIS Presentations, Including an Oral Presentation, at the Upcoming ASH Meeting
30/11/2018 -
Lundbeck and Otsuka report positive phase II data for the combination treatment of brexpiprazole and sertraline for the treatment of Post-Traumatic Stress Disorder (PTSD)
30/11/2018 -
La FDA américaine approuve le test de mutation LeukoStrat CDx FLT3 d’Invivoscribe comme CDx et le médicament XOSPATA (fumarate de gilteritinib) d’Astellas pour le traitement des patients atteints de LMA aux États-Unis
30/11/2018 -
Aino Health AB (publ): Aino Health and Finla in joint client project
30/11/2018
Pages